Log in to search using one of your social media accounts:

 

Aerie launches Ph3 trial for Roclatan eye drug in Europe
Aerie Pharmaceuticals (NSDQ:AERI) said today that it launched its European Mercury 3 late-stage trial of Roclatan in patients with open-angle glaucoma or ocular hypertension. The eye drug is a fixed dose combination of Aerie’s Rhopressa netarsudil ophthalmic solution and a widely-used prostaglandin analogue, latanoprost. The company’s Phase III trial was designed to support regulatory approval and commercialization in Europe, Aerie said. Get the full story at our sister site, Drug Delivery Business News. The post Aerie launches Ph3 trial for Roclatan eye drug in Europe appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - September 6, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Optical/Ophthalmic Pharmaceuticals Wall Street Beat Aerie Pharmaceuticals Source Type: news

BioLight ’ s glaucoma insert succeeds in Phase I/IIa trial
BioLight Life Sciences (TLV:BOLT) touted data today from a Phase I/IIa clinical trial evaluating its Eye-D latanoprost insert. The device successfully lowered intraocular pressure during the study’s 12-week period and had a favorable safety profile, according to the Israel-based company. Get the full story at our sister site, Drug Delivery Business News. The post BioLight’s glaucoma insert succeeds in Phase I/IIa trial appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - July 24, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Optical/Ophthalmic Pharmaceuticals Research & Development Wall Street Beat biolightlifesciences Source Type: news

Inotek ’s trabodenoson shows no clinical advantage in Phase II FDC trial for glaucoma
Inotek Pharmaceuticals has reported top-line results from the Phase II fixed-dose combination (FDC) trial of trabodenoson and latanoprost in patients suffering from glaucoma. (Source: Drug Development Technology)
Source: Drug Development Technology - July 9, 2017 Category: Pharmaceuticals Source Type: news

Lexington ’s Inotek suggests it could explore sale after another trial flop
Lexington-based Inotek Pharmaceuticals said Friday it is exploring “strategic alternatives” — corporate shorthand for a possible sale or other major transaction — after its lead drug for glaucoma flunked another big study. Inotek (Nasdaq: ITEK) announced the failure of a Phase 2 study in which patients received the company’s drug, called trabodenoson, al ong with another glaucoma eye drop, Pfizer’s Xalatan. According to Inotek, patients saw a reduction in eye pressure after four weeks… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - July 7, 2017 Category: Biotechnology Authors: Max Stendahl Source Type: news

Lexington ’s Inotek suggests it could explore sale after another trial flop
Lexington-based Inotek Pharmaceuticals said Friday it is exploring “strategic alternatives” — corporate shorthand for a possible sale or other major transaction — after its lead drug for glaucoma flunked another big study. Inotek (Nasdaq: ITEK) announced the failure of a Phase 2 study in which patients received the company’s drug, called trabodenoson, al ong with another glaucoma eye drop, Pfizer’s Xalatan. According to Inotek, patients saw a reduction in eye pressure after four weeks… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - July 7, 2017 Category: American Health Authors: Max Stendahl Source Type: news

Inotek closes enrolment in Phase II trial of trabodenoson + latanoprost for glaucoma
Inotek Pharmaceuticals has closed patient enrolment in the Phase II clinical trial of fixed-dose combination (FDC) of trabodenoson and latanoprost to treat patients with glaucoma. (Source: Drug Development Technology)
Source: Drug Development Technology - April 11, 2017 Category: Pharmaceuticals Source Type: news

Xalatan (Latanoprost Ophthalmic) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - January 4, 2017 Category: Drugs & Pharmacology Source Type: news

Aerie completes enrollment of phase III trial for intraocular pressure eye drops
Aerie Pharmaceuticals (NSDQ:AERI) said today that it completed enrollment for its 2nd phase III registration trial, Mercury 2, evaluating its Roclatan once-daily eye drops for intraocular pressure resulting from glaucoma or ocular hypertension. The company’s Roclatan solution is a fixed dose combination of its drug Rhopressa (netarsudil ophthalmic solution) and latanoprost, a widely prescribed prostaglandin analogue. More than 690 patients are enrolled in the 3-arm study, comparing the Roclatan solution to each of its individual components. Get the full story at our sister site, Drug Delivery Business News. The ...
Source: Mass Device - December 7, 2016 Category: Medical Equipment Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Optical/Ophthalmic Pharmaceuticals Wall Street Beat Aerie Pharmaceuticals Source Type: news

Skip the drops, Glaucoma patients look to drug-eluting contact lens
Daily medicated eye drops are the first line of treatment for glaucoma, the leading cause of irreversible blindness. The drops relieve pressure in the eye, a significant risk factor for glaucoma. But they’re not ideal: their delivery is imprecise, they can cause stinging and burning and patients often struggle to administer them. Adherence is poor: in one study based on insurance claims data, nearly half of patients who had filled a glaucoma prescription stopped topical glaucoma therapy within six months. Engineered contact lenses dispensing glaucoma medication gradually could vastly improve adherence, helping hang o...
Source: Mass Device - August 31, 2016 Category: Medical Equipment Authors: MassDevice Tags: Blog Vector Blog Source Type: news

Effect of Switching From Latanoprost to Bimatoprost in POAGEffect of Switching From Latanoprost to Bimatoprost in POAG
Is there a benefit to switching from latanoprost to bimatoprost? The medication change may help lower IOP in patients with primary open-angle glaucoma, a new study reports. Journal of Glaucoma (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 23, 2016 Category: Consumer Health News Tags: Ophthalmology Journal Article Source Type: news

Latanoprost eye drop for glaucoma more than halves vision loss
Two year placebo controlled trial backs use of most commonly prescribed prostaglandin analogueRelated items from OnMedicaAcute angle closure glaucomaPrimary open angle glaucoma Warning of big rise in age-related blindnessGP referral rates may partly explain national variation in squint surgeryChildren born with sight loss on the increase (Source: OnMedica Latest News)
Source: OnMedica Latest News - December 19, 2014 Category: UK Health Source Type: news

Latanoprost Preserves Vision in Open-Angle Glaucoma (FREE)
By Amy Orciari Herman Edited by André Sofair, MD, MPH, and William E. Chavey, MD, MS Latanoprost helps maintain visual field function in patients with open-angle glaucoma, according to an industry-supported study in the Lancet. … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - December 19, 2014 Category: Primary Care Source Type: news

Injection May Replace Drops to Lower Intraocular PressureInjection May Replace Drops to Lower Intraocular Pressure
A single injection of a nanoliposomal formulation of latanoprost significantly reduced pressure in patients with ocular hypertension or glaucoma, researchers report. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 6, 2014 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Aerie doses first patient in phase 2b study of glaucoma drug
US-based Aerie Pharmaceuticals has dosed its first patient in a phase 2b trial of PG324, a novel, fixed-combination of its AR-13324 and latanoprost, a prostaglandin analogue that is the most widely prescribed glaucoma drug. (Source: Drug Development Technology)
Source: Drug Development Technology - February 3, 2014 Category: Pharmaceuticals Source Type: news

Therapies for Patients With Glaucoma or Ocular HypertensionTherapies for Patients With Glaucoma or Ocular Hypertension
How does a latanoprost ophthalmic solution compare with xalatan in the treatment of glaucoma or ocular hypertension? Journal of Glaucoma (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - December 30, 2013 Category: Opthalmology Tags: Ophthalmology Journal Article Source Type: news

Innovative drug-dispensing contact lens delivers glaucoma medication continuously for a month
(Massachusetts Eye and Ear Infirmary) Researchers at Massachusetts Eye and Ear/Harvard Medical School Department of Ophthalmology, Boston Children's Hospital, and the Massachusetts Institute of Technology are one step closer to an eye drop-free reality with the development of a drug-eluting contact lens designed for prolonged delivery of latanoprost, a common drug used for the treatment of glaucoma, the leading cause of irreversible blindness worldwide. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - December 9, 2013 Category: Global & Universal Source Type: news

New Glaucoma Drug May Be More Effective Than LatanoprostNew Glaucoma Drug May Be More Effective Than Latanoprost
An experimental glaucoma medication might lower intraocular pressure more effectively than latanoprost without increasing adverse effects, report researchers. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 28, 2013 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Horizon scanning: latanoprostene bunod enters into phase III glaucoma study
Source: PharmaTimes Area: News According to a Pharmatimes report, latanoprostene bunod, a novel nitric oxide-donating prostaglandin F2-alpha analogue, will be evaluated in two phase III studies which will include approximately 800 patients with glaucoma or ocular hypertension. The primary endpoint is the reduction in mean intraocular pressure (IOP) measured at specified time points during three months of treatment.   In a phase IIb study in 413 patients, the drug demonstrated that all four doses showed greater IOP reduction compared with latanoprost; the differences for two of the four doses reached statistical s...
Source: NeLM - News - January 30, 2013 Category: Drugs & Pharmacology Source Type: news